Trial site
Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz
- 34running trials
- 24closed trials
The trials here
What the 59 trials at this site are about, from their registry records.
- Conditions
- Lung cancer20 trials
- Ulcerative colitis8 trials
- Psoriasis6 trials
- Psoriatic arthritis6 trials
- Crohn's disease5 trials
- Heart failure3 trials
- Myeloproliferative neoplasms2 trials
- Obesity2 trials
- Stroke2 trials
- Type 2 diabetes2 trials
- Ankylosing spondylitis1 trial
- Asthma1 trial
- and 8 more
- Phase
- Phase 343 trials
- Phase 214 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Completed23 trials
- Recruiting18 trials
- Active, not recruiting13 trials
- Not yet recruiting3 trials
- Suspended1 trial
- Withdrawn1 trial
- Lead sponsor
- AstraZeneca10 trials
- Janssen Research & Development, LLC5 trials
- Hoffmann-La Roche3 trials
- Takeda3 trials
- Amgen2 trials
- and 31 more
Running trials
Recruiting
Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Recruiting
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Recruiting
Recruiting
Active, not recruiting
A study to test if SRSD107 prevents venous thromboembolism events and how safe it is
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Recruiting
Recruiting
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Active, not recruiting
Recruiting
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
Recruiting
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Active, not recruiting
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Active, not recruiting
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer9 recruiting
- Crohn's disease3 recruiting
- Heart failure2 recruiting
- Ulcerative colitis2 recruiting
- Bladder cancer1 recruiting
- Myelodysplastic syndromes1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Obesity1 recruiting
- Psoriasis1 recruiting
- Psoriatic arthritis1 recruiting
- Stroke1 recruiting
Closed trials
Withdrawn
Completed
Completed
Active, not recruiting
Completed
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
Active, not recruiting
Completed
Completed
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Completed
Completed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Active, not recruiting
Completed
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.
Completed
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Completed
Active, not recruiting
Active, not recruiting
Completed
Completed
Terminated
Completed
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC
Completed
Completed
Active, not recruiting
Site data: EU CTIS (euclinicaltrials.eu)Updated 19 Nov 2026